Oral Session 3-15D AML: Novel Therapy

[OS3-15D-2] Outcomes of tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Eunice S. Wang¹, Andrew Lane³, Kendra Sweet⁴, Marina Konopleva², Shay Shemesh⁵, Ivan Bergstein⁵, Christopher Brooks⁵, Naveen Pemmaraju² (1.Chief, Leukemia Service Professor of Oncology, Dept Medicine Director, Hematologic Procurement Shared Resource Department of Tumor Immunology Roswell Park Comprehensive Cancer Institute, Buffalo, NY, United States of America, 2.The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, 3.Dana-Farber Cancer Institute, Boston, MA, United States of America, 4.H. Lee Moffitt Cancer Center, Tampa, FL, United States of America, 5.Stemline Therapeutics, Inc, New York, NY, United States of America)